Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process.
|
|
- Amos Austin
- 5 years ago
- Views:
Transcription
1 Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. This questionnaire is for Jardiance (empagliflozin). Patient Groups have to register before completing the questionnaire. Not sure your group is registered? Check our list of registered groups. Your group can complete this patient group questionnaire only once. If you submit multiple questionnaires, only your last submission will be sent to the Drug Benefit Council for consideration. To protect the privacy of members in your group, please do not include in your response names of individuals or companies, locations, or any other information that might identify them or anyone else. Completing the questionnaire Mandatory questions are flagged with a red asterisk (*). If you decide not to provide the required information, click the CANCEL button at the bottom of this page to exit the questionnaire. To protect your privacy, your browser window will close. You do not need to answer all the optional questions. You need only answer those that you think apply to patients in your group. To protect your privacy, please close this browser window after you complete this questionnaire. Respondent information To have your input accepted, you must complete the Confirmation of Eligibility, Contact Information and Conflict of Interest Declaration sections of this questionnaire. Confirmation of eligibility 1. I am a resident of British Columbia, AND
2 I am an authorized member of a Patient Group that represents B.C. patients who have the condition or disease for which this drug is used.* x Yes No Contact Information Your organization's contact information will only be used to retrieve your submission if you submit a request under the Freedom of Information and Protection of Privacy Act (FOIPPA). It will not be used for any other purpose. Your organization's name, however, will be included as part of your submission to the Drug Benefit Council. 2. Patient Group Name and name of representative completing this questionnaire* Patient Group Name: Canadian Diabetes Association Submitted by: Serge Corbeil, Director, Government Relations and Advocacy, BC and Alberta 3. Organization's Address * Canadian Diabetes Association, BC Office West 8th Avenue Vancouver, BC 4. Postal Code * V6H 3V9 Conflict of Interest Declaration To make sure the Drug Review process is objective and credible, everyone who provides input has to tell us about any possible conflict of interest. A conflict of interest exists if you, an immediate family member or your organization might benefit from the outcome of the review. For example, if you or your family own stock in the company that makes the drug, there could be a financial benefit IF PharmaCare decides to cover the drug. If your organization receives funding from the drug company, there could be a financial benefit (such as ongoing or increased funding) IF PharmaCare decides to cover the drug. Examples of conflicts of interest include, but are not limited to, financial support from the pharmaceutical industry (e.g., educational or research grants, honoraria, gifts and salary) as well as affiliations or commercial relationships with drug manufacturers or other interest groups. Even if you or an immediate family member, or your organization, has a conflict of interest, your input will still be considered as long as you declare the conflict of interest in your answers to the questions. All information you provide is protected under the Freedom of Information and Protection of Privacy Act. 5. Do you have any Conflict(s) of Interest to declare?
3 (If you answer "yes," please complete Question 6 below.)* xyes No 6. Describe any Conflict(s) of Interest below. (Complete this question only if you answered "yes" to the previous question) The Canadian Diabetes Association (the Association) solicits and receives unrestricted educational grants from manufacturers/vendors of medications, supplies and devices for diabetes and its complications. These funds help the Association to support community programs and services for people with diabetes, fund research and advocacy, across Canada. Sponsors were not involved in developing the content of this submission. Questions on drug under review Question 7 is mandatory; all other questions in this section are optional. 7. Have you read the PharmaCare information sheet for this drug?* If you would like to read this information now, click on the "this drug's information sheet" link in the What this drug is for column of the List of Drugs Under Review. The information sheet will open in a new window.* x Yes, I have read the information sheet No, I have not read the information sheet 8. Describe how the condition or disease for which this drug is used affects the day-today life of patients in your group. Type 2 diabetes is a chronic (progressive) condition that occurs when the pancreas does not produce enough insulin or when the body does not effectively use the insulin that is produced. Insulin is a hormone that controls the amount of glucose in the blood. Common symptoms of diabetes include fatigue, thirst and weight change. High blood glucose levels can cause long-term complications such as blindness, heart disease, kidney problems, nerve damage and erectile dysfunction. Diabetes requires considerable self-management, including healthy eating, regular physical activity, healthy body weight, taking diabetes medications (oral and/or injection) as prescribed, monitoring blood glucose and stress management. Poor glucose control can result in serious long-term complications. The majority of patients surveyed indicated that daily fluctuations in blood sugar were the most important aspect of diabetes to control during the day and overnight. The fluctuations impact the ability to work, interactions with friends and family, causes stress and worry as well as ability to participate in normal activities of daily living. Uncontrolled diabetes and the stigma associated with the disease can result in reduced quality of life. Maintaining control of diabetes has potential to reduce anxiety and avoid or delay complications as well as improve overall quality of life. Information presented in this section is derived from surveys conducted in 2014 and 2015 by the Canadian Diabetes Association (the CDA), distributed through social media and blasts. These surveys asked about the reality and challenges of living with type 2 diabetes.
4 There was a frequent emphasis on the psychological and emotional impact of diabetes on the lives of respondents (effect on stress, anxiety, adjusting to changes in diet and lifestyle, medication and treatment management as well as relationships with family). Respondents also described fatigue and lack of energy. Management of diabetes includes lifestyle changes (diet, exercise and stress management). Inevitably, most patients are prescribed one or more medications to achieve glucose control. This usually starts with metformin (oral agent) and, if target glucose levels are not met, other medications are added. Over time most patients will be treated with multiple diabetes medications in order to achieve glycemic control. Below are selected quotes from respondents to our surveys when asked about challenges related to diabetes: Having diabetes makes me useless. I have no energy or strength to enjoy life anymore. I can't do partial jobs around house. I can't enjoy sports anymore. Diabetes has instill [sic] a fear in me. It is a life altering disease that impacts every aspect of life. There is constant blood monitoring, diet, level of activity, cost of expensive supplies and medication. Basically it's an awful experience, experience highs and lows. Exercising can make my sugars low so I have to always have a snack with me. Eating anywhere besides home is a challenge as you don't know how things are made. I'm constantly checking my blood and I take 13 pills a day. The most distressing side effect of all of the diabetes drugs is they make you gain weight or prevent weight loss. It is annoying to be told to lose weight then handed a drug that prevents weight loss 9. If the patients in your group have tried the drug under review, please tell us about the effects they experienced. The availability of empagliflozin to offer an alternative treatment option for stabilizing blood glucose is important to patients. Empagliflozin belongs to a new class of drugs to lower blood glucose through inhibition of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. The SGLT2 inhibition also causes a reduction in blood pressure and weight loss. Information presented below was originally gathered from a survey conducted in April 2015 about the experience with SGLT2 inhibitor drugs empagliflozin (Jardiance) and dapagliflozin (Forxiga), to inform a patient input submission to the CDR. Questions from these surveys included current drug therapy, previous experience with drug therapy and experience with empagliflozin (Jardiance) and dapagliflozin (Forxiga). Data have been extracted from that survey for this submission. A total of 56 British Columbians completed the survey, 50 identified themselves as being diagnosed with type 2 diabetes, 4 indicated they were caregivers for people with type 2 diabetes. Given that empagliflozin was not currently available on the market in B.C., only 2 respondents indicated they have taken empagliflozin; 15 have taken Forxiga which is in the same class. Due to the small number of responses for Jardiance alone, we will report on respondents experience using this class. B.C. residents who have taken Jardiance/Forxia noted its effectiveness in reducing blood sugar levels. Those who have not taken this drug want to see if the drug can reduce weight gain, high blood pressure, and
5 think the drug should be offered as an option to help people where the other drugs don t. Those who have taken one of the SGLT2 inhibitors noted instant improvement in blood glucose control ( instant reduction in sugar levels ) and weight loss ( lost about 3 5 lbs in a week ). Some also felt more energetic and did not experience side effects. Others felt dehydration, more and frequent urination. One commented that it seems to be doing the job where the other was not quite working. B.C. residents that responded to the survey indicated the most important benefits of a drug include its ability to keep blood glucose at target, to minimize side effects and affordability. Many also indicated it is important that the drug keeps them away from the needle or reduce insulin and dependence on multiple drugs. Many hope the drug will help them to lead as normal life as possible. 10. What drugs or other treatments have the patients in your group used, or are currently using, for the condition or disease for which this drug is used? Please list all of the drugs and tell us about the experience of the patients in your group with each treatment. Patients that answered our survey expressed preference for oral drugs ( hopefully [the drug can] reduce/eliminate need for injected insulin ) and for fewer pills needed for a day. In addition to Jardiance and Forxiga, respondents did not comment on the experience of other specific drugs. Below we provide the list of drugs respondents indicated they are currently using, and the percentages of people using these drugs: - Invokana (6%) - Kazano (3%) - DPP-4 inhibitors (11%) - Komboglyze (6%) - Janumet (8%) - Jentadueto (6%) - Avandamet (3%) - Metformin (75%) - Sulfonylurea (31%) - Meglitinides (3%) - TZDs (6%) - GLP-1 agonists (12%) - Insulin (51%) Three quarters of the respondents are currently on metformin, half of them are currently on insulin, and one-third are using a sulfonylurea. While the majority of the respondents indicated satisfaction with their current treatment, 20% indicated they are dissatisfied with the treatment, and 18% reported they are neither satisfied nor dissatisfied. 11. Please tell us why your organization believes this drug should be included in the BC PharmaCare program. Diabetes requires intensive self-management. To achieve optimal blood glucose levels, individualization of
6 therapy is essential, including selecting the drug or combination of drugs, route of administration (oral, injection, pen or pump), how frequently the patient monitors blood glucose and adjusts dosage, the benefits and risks that the patient experiences and/or tolerates, and the lifestyle changes the patient is willing or able to make. There are clear expectations that any new drugs should offer good blood glucose control to prevent hyperglycemic and hypoglycemic episodes, as well as longer term control, with minimal side effects and long term damage to organs, and at affordable costs. Many patients also hope that new medications can help reduce the number and types of drugs taken including insulin injections. The patients who have had experience with empagliflozin and dapagliflozin described good results in terms of glucose control and less side effects. Different people living with diabetes require different options in terms of medications to help effectively manage their disease. Their clinical profile, preference and tolerance of therapy can direct physicians to the most appropriate drug therapy. As noted by a respondent: Every person has their own response to a drug... The [doctor] needs to be able to prescribe what is best for that patient (in regards to efficacy & or side effects.) The availability of empagliflozin (Jardiance) provides an important option for patients. Conclusion Thank you for your organization's input to B.C. PharmaCare's review of this drug. Once the survey period for this drug ends, we will send everyone's responses to the Drug Benefit Council for consideration when they make their drug coverage recommendations. Before your input is forwarded to the Drug Benefit Council, we will remove all personal information, including the name(s) of patients and any other identifying details. The name of your organization, however, will be included as part of your submission.
Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process.
Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. This questionnaire is for Forxiga (dapagliflozin). Patient Groups have to register before
More informationCommon Drug Review Patient Group Input Submissions
Common Drug Review Patient Group Input Submissions Jardiance (empagliflozin) Type 2 diabetes Patient group input submissions were received from the following patient groups. Those with permission to post
More informationCommon Drug Review Patient Group Input Submissions
Common Drug Review Patient Group Input Submissions empagliflozin and metformin (Synjardy) for Diabetes mellitus (Type 2) Patient group input submissions were received from the following patient groups.
More informationB.C. PHARMACARE S PUBLIC INPUT QUESTIONNAIRE FOR DRUGS BEING REVIEWED UNDER THE B.C. DRUG REVIEW PROCESS
B.C. PHARMACARE S PUBLIC INPUT QUESTIONNAIRE FOR DRUGS BEING REVIEWED UNDER THE B.C. DRUG REVIEW PROCESS Drug Under Review: insulin glargine-lixisenatide (Soliqua) Date Submitted: October 17, 2018 Confirmation
More informationSection 1 General Information
Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group Name of primary contact for this submission: Name of author (if different) Position
More informationPatient Input Template for CADTH CDR and pcodr Programs. Name of the Drug and Indication. Insulin degludec (Tresiba), type 1 and type 2 diabetes
Patient Input Template for CADTH CDR and pcodr Programs Name of the Drug and Indication Name of the Patient Group Author of the Submission Name of the Primary Contact for This Submission Insulin degludec
More informationCanadian Diabetes Association Patient Input Submission to CADTH New Drugs for Type 2 Diabetes:
Canadian Diabetes Association Patient Input Submission to CADTH New Drugs for Type 2 Diabetes: Name of patient group Patient group s website Canadian Diabetes Association www.diabetes.ca Date submitted
More informationPatient Input for CADTH CDR and pcodr Programs
Patient Input for CADTH CDR and pcodr Programs Name of the Drug and Indication Name of the Patient Group Author of the Submission Name of the Primary Contact for This Submission Email Insulin lispro biosimilar
More informationType 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?
Patient decision aid Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options? nice.org.uk/guidance/ng28 Published: December 2015 About this decision
More informationCASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
More informationCopyright 2003 How long does it take metformin to lower blood sugar. All rights reserved.
How long does it take to see results with invokana on lowering your sugar reading?. Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationType 2 diabetes and the role of GLP-1
Type 2 diabetes and the role of GLP-1 Putting the puzzle pieces of type 2 diabetes together In people with type 2 diabetes, there are at least 8 core defects that can affect blood sugar levels. Doctors
More informationCHAPTER 2: Mental health and perception of diabetes
CHAPTER 2: Mental health and perception of diabetes There is a strong link between diabetes and mental health challenges. Both the diagnosis of diabetes and the demands of diabetes management often lead
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More information2. The charges will be sent to the insurance company on one bill, but will list each date that you come to a class.
614-447-9495, ext. 1 You are scheduled to attend a series of four diabetes education classes. If you are not able to attend the class series, we ask that you cancel your appointment at least 48 working
More informationHow can I access flash glucose monitoring if I need it? Support pack. This pack will help you to find out more about flash and how you can access it.
How can I access flash glucose monitoring if I need it? Support pack This pack will help you to find out more about flash and how you can access it. Reviewed March 2019 Introduction Following several major
More informationDiabetes: Just the Basics
Diabetes: Just the Basics Newly Diagnosed Type 2 Diabetes If you have recently been diagnosed with diabetes, you may be experiencing a range of emotions. You should know that you are not alone. Your healthcare
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationFamily & Individual Support Program - Handbook
Family & Individual Support Program - Handbook Welcome and Introduction to the Simon Fraser Society for Community Living Welcome to the Simon Fraser Society for Community Living (SFSCL). We have been serving
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationCANADIAN DIABETES ASSOCIATION
CANADIAN DIABETES ASSOCIATION Submission to the PREMIER S CONVERSATION ON HEALTH July 2007 Canadian Diabetes Association 360 1385 West 8 th Avenue Vancouver, BC V6H 3V9 Phone: (604) 732-1331 Fax: 604-732-8444
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationStanford Youth Diabetes Coaches Program Instructor Guide Class #1: What is Diabetes? What is a Diabetes Coach? Sample
Note to Instructors: YOU SHOULD HAVE ENOUGH COPIES OF THE QUIZ AND THE HOMEWORK TO PASS OUT TO EACH STUDENT. Be sure to use the NOTES view in Powerpoint for what to cover during class. It is important
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationPatient Group Input to CADTH
Patient Group Input to CADTH from: Section 1 General Information Name of the therapeutic review Name of patient group Pulmonary Arterial Hypertension Therapeutic Review Patient Group s contact information
More informationCommon Drug Review Patient Group Input Submissions
Common Drug Review Patient Group Input Submissions tolvaptan (Jinarc) for Autosomal dominant polycystic kidney disease (ADPKD) Patient group input submissions were received from the following patient groups.
More informationSection 3 Information About the Submitting Patient Group. Canadian Diabetes Association and the Consumer Advocare Network. Name of the patient group
Section 3 Information About the Submitting Patient Group Name of the drug Indication of interest Name of the patient group Basaglar (insulin glargine SEB) Type 1 and type 2 diabetes Canadian Diabetes Association
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationAm I at Risk for Type 2 Diabetes?
Am I at Risk for Type Diabetes? Taking Steps to Lower Your Risk of Getting Diabetes On this page: What is type diabetes? Can type diabetes be prevented? What are the signs and symptoms of type diabetes?
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationUsing New Guidelines to Improve Best Practices in Obesity Management
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAm I at Risk for Type 2 Diabetes?
NATIONAL DIABETES INFORMATION CLEARINGHOUSE Am I at Risk for Type 2 Diabetes? Taking Steps to Lower Your Risk of Getting Diabetes U.S. Department of Health and Human Services National Institutes of Health
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE TREATMENT OF HYPERGLYCEMIA - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT
More informationChecking your. blood sugar. How frequent blood sugar checks can help you. When to check your blood sugar. Keeping a blood sugar tracker
Checking your blood sugar How frequent blood sugar checks can help you Checking your blood sugar yourself is an important part of managing diabetes. Checking often will tell you: If your insulin or other
More informationStandard Medicare and Managed Medicare plans pay for diabetes education.
614-447-9495, ext. 1 You are scheduled to attend a series of four diabetes education classes. If you are not able to attend the class series, we ask that you cancel your appointment at least 48 working
More informationABOUT TYPE 2 DIABETES
ABOUT TYPE 2 DIABETES Because the more you know, the better you ll feel. What You ll Find Attitudes and Beliefs Type 2 Diabetes What Is It? Where You ll Find It Page 4-5 This booklet is designed to help
More informationThe emotional side of diabetes
The emotional side of diabetes Diabetes can take a lot of effort to manage. So it s not surprising that many people who have it feel overwhelmed. If you have felt that way, you re not alone. Read on to
More informationClinical Trials: Improving the Care of People Living With Cancer
CLINICAL TRIALS Clinical Trials: Improving the Care of People Living With Cancer Presented by Mary McCabe, RN, MA Memorial Sloan-Kettering Cancer Center Carolyn Messner, DSW CancerCare Learn about: Stages
More informationWhat are your concerns? 3. Information about diabetes and treatment 5. About insulin therapy 6. Knowing your blood sugar 7. What are your choices?
Contents What are your concerns? 3 Information about diabetes and treatment 5 About insulin therapy 6 Knowing your blood sugar 7 What are your choices? 9 Advantages and disadvantages of the treatment options
More information1 Information about the Patient Advocacy Group
1 Information about the Patient Advocacy Group Name of the drug and indication(s): Name of registered patient advocacy group: Yervoy (Ipilimumab) First Line Save Your Skin Foundation Contact person: Title:
More information21 Diabetic Myths Exposed
21 Diabetic Myths Exposed Disclaimer: Nothing in this ebook should be taken as complete medical advice. You should always seek the advice and treatment from certified and qualified medical personal. Contents
More informationWhat is diabetes? What happens in diabetes? The most common types of diabetes are type 1 and type 2. Type 2. Type 1. In people without diabetes:
If you or someone you know has diabetes, you re not alone. Millions of people have diabetes. Diabetes cannot yet be cured. But it can be managed. The most common types of diabetes are type 1 and type 2
More informationPatient Group Submission Form
Patient Group Submission Form The Scottish Medicines Consortium (SMC) is committed to working in partnership with patient groups to capture patient and carer experiences, and use them to inform decision-making.
More informationA Clinical Context Report
Type 2 Diabetes in Practice An Expert Commentary with Silvio E. Inzucchi, MD A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationPatient Input Template for CADTH CDR and pcodr Programs
Patient Input Template for CADTH CDR and pcodr Programs Name of the Drug and Indication Name of the Patient Group Author of the Submission Name of the Primary Contact for This Submission Email Herceptin-Perjeta
More information1 Information about the Patient Advocacy Group
1 Information about the Patient Advocacy Group Name of the drug and indication(s): Pembrolizumab for Melanoma Name of registered patient advocacy group: Save Your Skin Foundation Contact person: Title:
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationAfter Soft Tissue Sarcoma Treatment
After Soft Tissue Sarcoma Treatment Living as a Cancer Survivor For many people, cancer treatment often raises questions about next steps as a survivor. What Happens After Treatment for Soft Tissue Sarcomas?
More informationHyperglycemia Procedure: Management and Treatment Adult Patients
Approved by: Chief Operating Officer; and Chief Medical Officer Hyperglycemia Procedure: Management and Treatment Corporate Policy & Procedures Manual Number: VII-B-465 Date Approved January 23, 2018 Date
More informationPatient Group Input Submissions
CADTH COMMON DRUG REVIEW Patient Group Input Submissions abobotulinumtoxina (Dysport Therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.) Indication: To reduce the subjective symptoms and objective signs
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationdiabetes medicines what are your options? ons?
diabetes medicines what are your options? ons? This booklet belongs to: Name Address City State ZIP Phone E-mail If this booklet is found, please contact the owner listed above. Thank you! Favorably reviewed
More informationResources relevant for 6 7 year olds
Resources relevant for 6 7 year olds Guide for healthcare professionals This guide outlines the goals of diabetes education for your 6 7 year old patients. Use this guide as part of a narrative discussion
More informationPatient Input CADTH COMMON DRUG REVIEW. VIBERZI (ELUXADOLINE) (Allergan Pharma Co.) Indication: Irritable bowel syndrome with diarrhea
CADTH COMMON DRUG REVIEW Patient Input VIBERZI (ELUXADOLINE) (Allergan Pharma Co.) Indication: Irritable bowel syndrome with diarrhea CADTH received patient input from: Gastrointestinal Society March 16,
More informationDiabetes on the Road There are only two choices. Tom Milam President TrueLifeCare
Diabetes on the Road There are only two choices Tom Milam President TrueLifeCare Who gets diabetes? I HATE DIABETES Impact on professional drivers The Population: 1.9+ million tractors registered in U.S.
More informationAfter Adrenal Cancer Treatment
After Adrenal Cancer Treatment Living as a Cancer Survivor For many people, cancer treatment often raises questions about next steps as a survivor. Lifestyle Changes After Treatment for Adrenal Cancer
More informationWelcome to Pathways. - Auckland - Information about Pathways services in the Auckland region.
Welcome to Pathways - Auckland - Information about Pathways services in the Auckland region. Alongside you in your recovery journey Welcome to Pathways. We re here to support you in your journey to being
More informationNCI Community Oncology Research Program Kansas City (NCORP-KC)
NCI Community Oncology Research Program Kansas City (NCORP-KC) Consent Form Study Title for Study Participants: Comparing Two Dose Levels of Bupropion Versus Placebo for Sexual Desire Official Study Title
More informationDiabetes and stroke. What is the link between diabetes and stroke? What is diabetes? What are the symptoms of diabetes?
Call the Stroke Helpline: 0303 3033 100 or email: info@stroke.org.uk Diabetes and stroke Diabetes is a lifelong condition that occurs when your body cannot regulate the amount of sugar in your blood. If
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationMood Disorders Society of Canada Mental Health Care System Study Summary Report
Mood Disorders Society of Canada Mental Health Care System Study Summary Report July 2015 Prepared for the Mood Disorders Society of Canada by: Objectives and Methodology 2 The primary objective of the
More informationWhat do diabetes medicines do?
What do diabetes medicines do? Over time, high levels of blood glucose, also called blood sugar, can cause health problems. These problems include heart disease, heart attacks, strokes, kidney disease,
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationSt. Jude Parish Survey Results
St. Jude Parish Survey 2013 Results Why Do a Survey Now? Last parish survey was 10 years ago Community (population, economic level, etc.) has changed, so it s likely our parishioners have changed as well
More informationJUST DIAGNOSED WITH DIABETES?
JUST DIAGNOSED WITH DIABETES? Being told that you have diabetes can be a real shock. And learning to live with it can be a challenge. You might be going through all sorts of emotions. It s perfectly normal
More informationREFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Januvia for Type 2 diabetes in the 10 major pharmaceutical markets
More informationFamily & Individual Support Program - Handbook
Family & Individual Support Program - Handbook Welcome to the Simon Fraser Society for Community Living (SFSCL). The SFSCL is an accredited not-for-profit, charitable organization that has been serving
More informationLiving Well with Diabetes. Meeting 12. Welcome!
12-1 Welcome! Welcome back and congratulations! Today is a time to celebrate all of your accomplishments. For the past few months we have learned a great deal about managing diabetes. Today, we will talk
More informationUnderstanding Common Medical Issues Session 5
1 Housekeeping items Washrooms Refreshment breaks Introductions 2 Learning Objectives To identify how the body produces insulin, how it is used and causes that reduce the efficiency of insulin production.
More informationVIDEO_ Sarah Hallberg - Interview (San Diego 2017)
VIDEO_ Sarah Hallberg - Interview (San Diego 2017) Dr. Andreas Eenfeldt: If you are a doctor and you want to help your patients with type 2 diabetes to reverse their disease, how do you do it? You can
More informationDiabetes. Diabetes in Balance
Diabetes Introduction to Diabetes If you are living with type 2 diabetes, it is important that your lifestyle has the right balance between the appropriate treatment, regular exercise and a healthy diet.
More informationThe TRUE Guide to Diabetes Care
monitor track manage A TRUEinsight Guide manage The TRUE Guide to Diabetes Care Important Questions and Informative Answers for People With Diabetes A Guide to Diabetes Care You ve been diagnosed with
More informationDiabetes Remission with Weight Loss - Frankly Speaking EP 49
Diabetes Remission with Weight Loss - Frankly Speaking EP 49 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media
More informationSMS USA PHASE ONE SMS USA BULLETIN BOARD FOCUS GROUP: MODERATOR S GUIDE
SMS USA PHASE ONE SMS USA BULLETIN BOARD FOCUS GROUP: MODERATOR S GUIDE DAY 1: GENERAL SMOKING QUESTIONS Welcome to our online discussion! My name is Lisa and I will be moderating the session over the
More informationPancreas transplants. What you need to know. Information for patients Sheffield Kidney Institute (Renal Unit)
Pancreas transplants What you need to know Information for patients Sheffield Kidney Institute (Renal Unit) page 2 of 16 What is the pancreas and why is it transplanted? The pancreas is part of the digestive
More informationWhat needs to happen in England
What needs to happen in England We ve heard from over 9,000 people across the UK about what it is like to live with diabetes and their hopes and fears for the future. Over 6,000 of them live in England;
More informationAdjusting Your Diabetes Medicine and Diet for a Test or Procedure
health information Adjusting Your Diabetes Medicine and Diet for a Test or Procedure The guidelines below will help you adjust your diabetes medicine and diet as you get ready for your procedure or lab
More informationAn eye for the big picture
An eye for the big picture When the Boehringer Ingelheim Science Department was founded 100 years ago, future Nobel Prize winner Heinrich Wieland ensured that this was done in a future-oriented way. Today,
More informationCommon Drug Review Patient Group Input Submissions
Common Drug Review Patient Group Input Submissions Pasireotide (Signifor) for Cushing s Disease Patient group input submissions were received from the following patient groups. Those with permission to
More informationOwn It! Control Your Blood Pressure
Own It! Control Your Blood Pressure PREP NOTE: Ask the facilitator to provide a brief, written introduction to share with the program participants. Also prepare your opening remarks. For example, you may
More informationVolunteer Satisfaction Survey
2017-18 Volunteer Satisfaction Survey The key points Making Norfolk a great place to grow older Contents Section 1 Introduction Section 2 Results Section 3 Actions Response rate Service type Length of
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationIs ketogenic diet good for diabetes type 1 or diabetes type 2? Diabetes & Ketogenic Diet: Can You Manage Your Diabetes On A Ketogenic Diet?
Diabetes: Reverse Diabetes Naturally & Safely: The Simple & Effective Changes You Can Make In Order To Reduce Blood Sugar Levels & Cure Diabetes... End Diabetes, Type 1 Diabetes, Insulin) By Jane Aniston
More informationMeet the many faces of pain
Meet the many faces of pain WWW.PRIALT.COM N O W M E E T Ziconotide is a synthetic equivalent of a naturally occurring conopeptide. Distributed by Elan Pharmaceuticals, Inc. (EPI). PRIALT is a registered
More informationREFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Empagliflozin for Type 2 diabetes in the 10 major pharmaceutical
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE GLYCEMIC MANAGEMENT - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT DOCUMENT
More informationmehealth for ADHD Parent Manual
mehealth for ADHD adhd.mehealthom.com mehealth for ADHD Parent Manual al Version 1.0 Revised 11/05/2008 mehealth for ADHD is a team-oriented approach where parents and teachers assist healthcare providers
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationDESANG MEET INPUT. diabetes magazine. The group helping diabetics find funding for pumps and CGM
DESANG diabetes magazine MEET INPUT The group helping diabetics find funding for pumps and CGM THIS article first appeared in Desang s free online magazine. LIVING LIVING KIT WHY INPUT MATTERS INPUT is
More informationYour Guide to a Smoke Free Future
Your Guide to a Smoke Free Future If you smoke, or if you have quit within the past 2 months, then ask for our detailed handout which provides information on how to begin and maintain a smoke-free lifestyle.
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationElizabeth: Sure. Well, CDE stands for Certified Diabetes Educator
Transcript Title: Talk It Out With Tim Tim: Hello, everyone. I'm Tim. And welcome to "Talk It Out." Super: Lantus MENTOR Super: Tim Taking Lantus (insulin glargine injection) 100 Units/mL SoloSTAR since
More informationThe Obstetrics and Gynaecology Health Psychology Service
Northumbria Healthcare NHS Foundation Trust The Obstetrics and Gynaecology Health Psychology Service Issued by the Obstetrics and Gynaecology Department Psychological therapy Everyone has different strategies
More informationGENERAL INFORMATION PROFESSIONAL REFERRAL INFORMATION
SO THAT WE MAY BETTER SERVE YOU, PLEASE COMPLETE THE FOLLOWING FORM AND EITHER BRING THE COMPLETED FORM WITH YOU TO YOUR FIRST APPOINTEMNT OR SCAN IT AND EMAIL IT TO OFFICE, PRIOR TO YOUR APPOINTMENT LORRAINE@ANALIPSONMD.COM
More information11 - Blood Tests (Completed 05/29/18) Transcript by Rev.com. Page 1 of 5
Megan: Hey everyone, I'm Megan Ramos, and I'm here today to answer your questions. Today's question involves lab tests, and what blood tests you should ask your doctor for. You can find a list of recommended
More informationObjectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT
Diabetes- The Real Cost of Sugar By Ruth Nekonchuk RD CDE LMNT Objectives To explain diabetes To explain the risks of diabetes To enumerate the cost of diabetes to our country To enumerate the cost of
More information